Three mitochondria-encoded subunits form the catalytic core of cytochrome c oxidase, the terminal enzyme of the respiratory chain. COX1 and COX2 contain heme and copper redox centers, which are integrated during assembly of the enzyme. Defects in this process lead to an enzyme deficiency and manifest as mitochondrial disorders in humans.
In Brief
Numerous assembly and chaperone proteins are involved in the biogenesis of cytochrome c oxidase (Complex IV), including COX2, which houses its redoxactive copper center. Pacheu-Grau et al. show that cytochrome c oxidase assembly factor 6 (COA6) is part of the COX2 copper relay system involving the copper metallochaperone SCO2. Mutations preventing SCO2/COA6 interactions underlie patient mitochondrial cardiomyopathies.
INTRODUCTION
The mitochondrial oxidative phosphorylation system generates the bulk of cellular ATP, fueling the energetic demands of most eukaryotes. Five multi-subunit protein complexes in the mitochondrial inner membrane, termed complexes I to V, comprise the oxidative phosphorylation system. These complexes are genetic hybrids. Thirteen core subunits of complexes I, III, IV, and V are encoded in the mitochondrial genome, while the remaining subunits are nuclear-encoded and imported into mitochondria (Mick et al., 2011; Soto et al., 2012) . Hence, enzyme complexes assemble from subunits that reach the inner membrane via different transport routes. Moreover, redox-active cofactors have to be inserted during maturation of respiratory chain complexes. In the case of cytochrome c oxidase (complex IV), which oxidizes cytochrome c and transfers electrons to molecular oxygen, the mitochondria-encoded COX1 and COX2 house the redox-active heme and copper centers. While COX1 contains two heme moieties (a and a 3 ) and the Cu B site, the Cu A site is positioned in the intermembrane space domain of COX2. A plethora of factors participate in the process of protein assembly and cofactor insertion, and perturbation of the assembly process causes a cytochrome c oxidase deficiency and severe disorders in humans.
Cytochrome c oxidase assembly initiates with the synthesis of COX1, which associates with assembly factors in the inner mitochondrial membrane, forming the MITRAC intermediate in humans. This association stabilizes COX1 and feedback-regulates the translation of COX1 mRNA. Insertion of heme, a process in which the SURF1 protein is implicated, is thought to occur once the first nuclear-encoded subunits have engaged with COX1. COX2 also spans the inner mitochondrial membrane, and contains soluble N-and C-terminal tails that protrude into the intermembrane space. OXA1 mediates export of the N-terminal tail of COX2 (Hell et al., 1997 (Hell et al., , 1998 , while COX18 is required for export of its C terminus (Fiumera et al., 2007; Saracco and Fox, 2002) . Delivery of copper to the Cu A site contained within the C-terminal tail of COX2 depends on a relay of metallochaperones in the intermembrane space. COX17 is crucial for copper delivery to both COX1 and COX2. The transfer of copper from COX17 to COX1 is facilitated by COX11 (Herrmann and Funes, 2005) . In the case of copper transfer from COX17 to the Cu A site, two related proteins, SCO1 and SCO2, are involved (Herrmann and Funes, 2005) . SCO1 participates in delivering copper to COX2 (Krummeck and Rö del, 1990; Rigby et al., 2008; Schulze and Rö del, 1988) , whereas the function of SCO2 has remained elusive. In yeast, Sco2 is dispensable for cytochrome c oxidase biogenesis but is nonetheless able to partially complement Sco1 deficiency, indicating that Sco1 and Sco2 have overlapping functions (Banci et al., 2011) . In contrast to yeast, human mitochondria possess two Sco1 homologs, termed SCO1 and SCO2, both of which are essential and have non-overlapping functions in the biogenesis of the Cu A site (Horng et al., 2005) . SCO2 has been proposed to act upstream of SCO1, hinting at a sequential copper delivery process for metallation of COX2 (Leary et al., 2004 (Leary et al., , 2009 ). After COX2 metallation, the COX1 and COX2 assembly lines merge and biogenesis of the enzyme complex continues by addition of COX3 and the other imported subunits.
Defects in heme a synthesis or delivery, as well as in copper chaperone function, have been linked to severe human disorders with cytochrome c oxidase deficiency. Patients with SCO1 mutations display cytochrome c oxidase deficiency, leading to fatal encephalopathy, hypertrophic cardiomyophathy, neonatal hepatopathy, and ketoacidotic comas (Stiburek et al., 2009; Valnot et al., 2000; Leary et al., 2013) . In contrast, mutations in SCO2 are associated with neonatal encephalocardiomyopathy (Papadopoulou et al., 1999) or hypertrophic cardiomyopathy (Jaksch et al., 2000) . Surprisingly, these distinct clinical phenotypes are not due to tissue-specific expression of SCO1 and SCO2, since both are ubiquitously expressed (Papadopoulou et al., 1999) . One explanation for this could be that other factors involved in COX2 maturation contribute to the tissue selective phenotype.
Exome sequencing approaches have now significantly extended the number of known pathogenic mutations affecting complexes of the oxidative phosphorylation system, expanding the set of factors putatively involved in the biogenesis of its enzyme complexes. One example for this is COA6. A recent sequencing study on infants with mitochondrial disorders identified a mutation in COA6 (C1orf31). The patient presented with hypertrophic cardiomyopathy, severe complex IV deficiency, and a mild reduction in complex I activity in heart tissue (Calvo et al., 2012) . A second COA6 patient, also with fatal hypertrophic cardiomyopathy, was recently reported (Baertling et al., 2015) . The yeast homolog of COA6 had been identified previously in a proteomic study as a mitochondrial intermembrane space protein (Ghosh et al., 2014; Vö gtle et al., 2012) . coa6D cells display reduced levels of cytochrome c oxidase (Ghosh et al., 2014; Vö gtle et al., 2012) . While a partial suppression of mutant phenotypes in the presence of high copper concentrations has been reported, the function of COA6 and why its loss leads to cardiomyopathy remains unknown (Baertling et al., 2015; Calvo et al., 2012; Ghosh et al., 2014) .
Here, we define the molecular function of COA6. We demonstrate that COA6 interacts with newly synthesized COX2 and that this interaction is conserved from yeast to man. In yeast mitochondria, Coa6 interacts with Sco1 and Sco2 preferentially in the absence of Cox2. In human mitochondria, COA6 selectively interacts with SCO2 in a COX2-dependent manner. A loss of COA6 leads to fast turnover of COX2, explaining the reduction in cytochrome c oxidase levels. Interestingly, pathogenic amino acid substitutions in both SCO2 and COA6 destabilize complex formation, thus linking the SCO2/COA6 interaction with the observed cardiac defect. We conclude that COA6 is a new constituent in the COX2 copper relay system, promoting SCO2 function during the metallation process.
RESULTS

COA6 Is Required for Cytochrome c Oxidase Biogenesis
In Saccharomyces cerevisiae, Coa6 is an intermembrane space protein that is released from mitochondria upon outer membrane opening and that is characterized by the presence of a Cx 9 Cx n Cx 10 C motif (Ghosh et al., 2014; Vö gtle et al., 2012) . Interestingly, COA6 is highly conserved from yeast to metazoa ( Figure S1 ). To assess the function of human COA6 (C1orf31) and understand how its malfunction leads to cardiomyopathy, we determined the localization of human COA6 by transfecting U2OS cells with COA6 containing a C-terminal FLAG-tag. Immunofluorescence microscopy demonstrated colocalization of COA6 FLAG with mitotracker labeling ( Figure 1A ). Next, we generated a stable HEK293T cell line expressing COA6 with a C-terminal FLAG tag. Carbonate extraction and detergent treatment released COA6 into the soluble fraction, while the integral membrane proteins TIM23 and MITRAC12 were only solubilized by detergent treatment ( Figure 1B ). Moreover, COA6 FLAG was present in isolated mitochondria where it only became accessible to externally added protease under conditions of outer membrane disruption, such as hypo-osmotic treatment (mitoplasts) or sonication ( Figure 1C ). Since defects in COA6 function cause cardiomyopathy in humans, we assessed expression levels of COA6 isoform 1 in different mouse tissues by qPCR. COA6 displayed increased expression in tissues with a high energy demand, such as heart, liver, and kidney ( Figure 1D ). Hence, no tissue-specific expression of COA6 was apparent, but rather an expression pattern resembling typical mitochondrial proteins (Vukotic et al., 2012; Yao and Shoubridge, 1999) .
To assess COA6 function, we established a cellular model in which we downregulated the amount of COA6 by siRNA treatment. Upon treatment of HEK293T cells with siRNA targeted against COA6, doubling of cells was significantly affected after 3 days and exacerbated after that ( Figure 1E ). To reduce nonspecific effects due to the loss of COA6, we harvested cells after 4 days of treatment for further analyses.
Since coa6D yeast cells display reduced levels of cytochrome c oxidase similar to patients carrying mutations in COA6, we assessed respiratory chain function upon COA6 knock-down. We analyzed the oxygen consumption rate of COA6 knockdown cells by real-time respirometry and observed drastically decreased oxygen consumption at basal and maximal capacity compared to control cells ( Figure 1F ). This phenotype was explained by significantly decreased cytochrome c oxidase activity and reduced overall levels of the enzyme complex ( Figure 1G ). Loss of activity and reduced cytochrome c oxidase content correlated with each other, indicating that enzyme activity directly reflects complex abundance ( Figure 1H ). Since defects in complex I activity had been described for one COA6 patient but were not apparent in a second pedigree (Baertling et al., 2015; Calvo et al., 2012) , we also measured the enzymatic activity and the total amount of complex I. Cells with reduced COA6 levels displayed a significant decrease in complex I activity and content ( Figure 1I ). Accordingly, a lack of COA6 caused complex I and complex IV defects in HEK293T cells.
COA6 Interacts with Newly Synthesized COX2 in Human and Yeast Mitochondria
Our results demonstrate that human COA6, similar to its yeast homolog, is required for cytochrome c oxidase function and biogenesis. However, how COA6 contributes to cytochrome c oxidase assembly remained to be assessed.
Assembly of cytochrome c oxidase is initiated with the synthesis of COX1, which engages with a multitude of assembly factors in the inner mitochondrial membrane to form an early assembly intermediate called MITRAC (Mick et al., 2012) . To address if COA6 was part of MITRAC in human mitochondria, we performed immunoprecipitation of MITRAC12 (Clemente et al., 2013; Mick et al., 2012 ) from wild-type and COA6 FLAG mitochondria. MITRAC12 coimmunoprecipitated known components of the MITRAC complex, such as COX1 and COX4-1. However, COA6 did not copurify with MITRAC12 (Figure 2A ), demonstrating that COA6 does not participate in early steps of COX1 assembly.
To analyze if COA6 interacts with other complexes containing newly synthesized mitochondria-encoded proteins, we radiolabelled mitochondrial translation products in COA6 FLAG or MITRAC12 FLAG cells and performed immunoisolation. As expected, COX1, and to a lesser extent other mitochondria-encoded subunits, copurified with MITRAC12 (Mick et al., 2012) . Interestingly, newly synthesized COX2 was isolated together with COA6 ( Figures 2B and S2A) .
COX2 is part of the catalytic core of cytochrome c oxidase and is conserved among species (Soto et al., 2012) . To assess if the COA6/COX2 interaction is conserved between human and yeast mitochondria, we labeled mitochondrial translation products and performed immunoprecipitations using antiserum directed against Coa6. Indeed, newly synthesized Cox2 was specifically (B) Mitochondria containing COA6 FLAG were subjected to carbonate extraction or detergent lysis, followed by differential centrifugation; pellet, P; supernatant, S; total, T. Samples were analyzed by SDS-PAGE and western blotting. (C) Submitochondrial localization analysis using COA6 FLAG mitochondria. Mito, mitochondria; MP, mitoplasts; Sonic., sonication; PK, proteinase K. Samples were analyzed by SDS-PAGE and western blotting. (I) Complex I activity and content in COA6 knock-down and control cells (SEM, n = 4). Enzymatic activity was determined by spectrophotometry, and amount of complexes was determined by ELISA. See also Figure S1 .
copurified with Coa6, indicating the conservation of this interaction and potentially COA6 function ( Figure 2C ). Because Cox2 was not significantly enriched in Coa6 immunoprecipitates by western blotting ( Figure S2B ), we conclude that the interaction between Cox2 and Coa6 is transient and only occurs early after Cox2 synthesis.
To address if absence of Coa6 in yeast mitochondria has a specific effect on Cox2, we analyzed steady-state protein levels in wild-type and coa6D mitochondria. The levels of Cox2 and other structural subunits of cytochrome c oxidase, such as Cox1 and Cox3, were reduced in coa6D mitochondria (Figure 2D ). The levels of nuclear-encoded COX subunits such as Cox5 and Cox6 were also reduced, albeit to a lesser extent. In contrast, the protein levels of assembly factors such as Coa1, Coa3, Shy1, and the translational regulator of Cox1, Mss51, were not affected ( Figure 2D ). In agreement with the observed reduction of cytochrome c oxidase on blue native PAGE (Ghosh et al., 2014; Vö gtle et al., 2012) , isolated coa6D mitochondria showed selectively decreased cytochrome c oxidase activity ( Figure 2E ).
COA6 Interacts with the Copper Insertion Machinery and Is Required for COX2 Stability
To address if Coa6 affects translation of the COX2 mRNA, we pulse-labeled mitochondrial translation products in yeast cells under conditions of inhibited cytosolic translation. Cox2 was barely detectable in coa6D cells ( Figure 3A ). This observation could be interpreted as an indication for reduced translation of Cox2 in cells lacking Coa6. To directly assess this possibility, we pulse-labeled mitochondrial translation products over a short time interval. We observed that less Cox2 was detectable with longer pulses in yeast cells lacking Coa6 ( Figure 3B ). Since a direct effect of Coa6 on mitochondrial ribosomes is unlikely, as Coa6 localizes to the intermembrane space, we assessed if newly synthesized Cox2 is destabilized in the absence of Coa6. We pulse-labeled mitochondrial translation products in wild-type and coa6D cells and monitored the fate of mitochondrial translation products over a brief 5 min chase period with unlabeled methionine. While the stability of Cox3 was largely unaffected ( Figure S3A ), newly synthesized Cox2 was rapidly turned over in the deletion strain, having a half-life of approximately 3 min ( Figure 3C ). It is interesting to note that Cox2 was also unstable after labeling translation products in isolated mitochondria. However, the kinetics of Cox2 turnover was slower than in intact cells, suggesting that mitochondrial dynamics or cellular organization may contribute to the quality control process in vivo (data not shown). In conclusion, absence of Coa6 in yeast cells leads to decreased amounts of Cox2 through increased protein turnover, eventually leading to a loss of cytochrome c oxidase.
Coa6 and its human homolog, COA6, are localized in the mitochondrial intermembrane space (IMS). Cox2 possesses two transmembrane spans, exposing a short N-terminal and a catalytic C-terminal tail into the intermembrane space ( Figure 3D ). In yeast, the N terminus of Cox2 undergoes proteolytic processing by the intermembrane space processing peptidase (IMP) (Nunnari et al., 1993) . Cox18 is required for export of the Cox2 C terminus into the IMS (Saracco and Fox, 2002) . We speculated that Coa6 interacts with either the soluble N-terminal or C-terminal domain of Cox2. Hence, we assessed the interaction of newly synthesized Cox2 with Coa6 in cox18D and imp1D mitochondria. In imp1D mitochondria, the interaction of Cox2 with Coa6 was similar to wild-type, indicating that N-terminal processing is not required for Coa6 binding. In contrast, no interaction between Cox2 and Coa6 was found in cox18D mitochondria (Figure 3E) . In cells lacking Cox18, the N terminus of Cox2 is inserted into the inner membrane and processed, and Cox2 is therefore resistant to protease degradation after swelling (Fiumera et al., 2007; Fiumera et al., 2009) and to carbonate extraction (Figure S3B) . Thus, we conclude that Coa6 interacts with Cox2 via its IMS-exposed C-terminal tail.
Cox1 is the central platform for assembly of cytochrome c oxidase. A regulatory feedback mechanism couples COX1 translation to its assembly, ensuring that Cox1 is synthesized at an appropriate rate (Fontanesi et al., 2008; Kim et al., 2012; Mick et al., 2011; Ott and Herrmann, 2010) . To assess if the interaction between Coa6 and Cox2 is affected in the absence of Cox1, we immunoprecipitated Coa6 after labeling of mitochondrial translation products in isolated mitochondria lacking Cox1. Similar amounts of Cox2 coimmunoprecipitated in cox1 À and wildtype mitochondria ( Figure 3F ). This finding indicates that the interaction between Coa6 and Cox2 occurs before incorporation of Cox2 into the Cox1 assembly line. The C-terminal domain of Cox2 forms a ten-stranded b-barrel containing the binuclear Cu A center (Tsukihara et al., 1996) . Taking this, and the presence of a Cx 9 Cx n Cx 10 C motif in Coa6, into account, we investigated the Cox2/Coa6 interaction in the context of proteins involved in copper delivery to Cox2. The delivery of copper to the Cu A site involves the metallochaperone Sco1. A related protein in yeast, Sco2, is dispensable for cytochrome c oxidase assembly but can compensate for loss of Sco1 upon its overexpression. Serendipitously, we detected Sco1 in Coa6 immunoprecipitations. Interestingly, Sco1 or Sco2 were not significantly recovered when Coa6 was precipitated from wild-type mitochondria, but only in cox2 À mutant mitochondria ( Figure 3F ). Based on this finding, we performed immunoprecipitation experiments using mitochondria from several mutant strains: pet111D, defective in Cox2 translation; rho 0 , lacking functional mitochondrial DNA; and cox18D. Only low amounts of Sco1 and Sco2 copurified with Coa6 in wildtype mitochondria. However, significantly increased copurification of Sco1 and Sco2 was observed in mitochondria lacking Cox2 (rho 0 , pet111D). Moreover, increased Sco1 and Sco2 copurification was apparent in cox18D mitochondria ( Figure 3G and Figure S3C ). The observed increased association between Coa6 and Sco1/Sco2 in the absence of Cox2 indicates that Coa6 plays a role in copper insertion/delivery. Hence, we analyzed copper binding of Coa6. We expressed and purified GST-Coa6, GSTSco1, and GST-Sco2 fusion proteins from E. coli cells. Copper content was assessed by atomic absorption spectrophotometry. While GST alone did not contain significant amounts of copper, GST-Coa6, GST-Sco1, and GST-Sco2 contained similar amounts of copper in this assay ( Figure S3D ). These data suggest that Coa6 is able to bind copper with an affinity similar to the Sco proteins when expressed in E. coli.
To assess if the interaction between Coa6 and Cox2 depends on the mitochondrial copper-relay system, we performed Coa6 immunoprecipitation after labeling of mitochondrial translation products in mitochondria from mutants lacking proteins involved in mitochondrial copper homeostasis. Cox17 is a copper-binding metallochaperone, containing a CCXC motif, and transfers copper to Sco1 and Cox11, which are responsible for copper insertion into the Cu A and Cu B sites, respectively (Carr et al., 2002; Glerum et al., 1996) . Sco2 and Sco1 display sequence similarity and have overlapping but not identical functions (Banci et al., 2011; Glerum et al., 1996; Leary, 2010) . Cox19 and Cox23 are putative copper chaperones localized to the intermembrane space. However, their function is still not well defined (Barros et al., 2004; Rigby et al., 2007) . The normalized amount of newly synthesized Cox2 that coimmunoprecipitated with Coa6 was considerably increased in cox11D, cox17D, cox19D, cox23D, and sco1D mitochondria, compared to wild-type ( Figures 3H  and S3E ). In contrast, deletion of SCO2 resulted in significantly decreased Cox2 copurification ( Figures 3H and S3E) . Thus, in the absence of copper chaperones involved in copper transfer to Cox2, Coa6 accumulated in a Cox2-associated state. In contrast, a lack of Sco2 led to an apparent loss of the Coa6/ Cox2 interaction ( Figures 3H and S3E) . Accordingly, in yeast, Coa6 interacted with Cox2 in a copper-chaperone-dependent manner. As the interaction between Sco1/2 and Coa6 was increased in the absence of Cox2, we conclude that Coa6 accumulates in a complex with the metallochaperones in the absence of its substrate. (legend continued on next page) (Chomyn, 1996; Mick et al., 2012) . Human mitochondria have two homologs of yeast Sco1, termed SCO1 and SCO2 (Soto et al., 2012) . Interestingly, COA6 FLAG specifically coisolated with SCO2, but not with SCO1. Moreover, treatment with thiamphenicol strongly affected the COA6/SCO2 interaction ( Figure 4A ). Accordingly, also in human mitochondria, COA6 interacted with metallochaperones of the SCO family. However, COA6 displayed SCO2 specificity and did not interact significantly with SCO1. Moreover, in human cells, COX2 is Figure 4B ). We radiolabelled mitochondrial translation products and isolated the COA6 FLAG -containing complex under native conditions. The purified complex was first separated on BN-PAGE and then subjected to a 2D separation on SDS-PAGE. Radiolabelled COX2 copurified with COA6 FLAG and comigrated together with COA6 and SCO2, suggesting that these proteins form a ternary complex ( Figure 4C ). Patients with mutations in SCO1 and SCO2 present with earlyonset mitochondrial disease in which affected tissues exhibit a cytochrome c oxidase deficiency and a profound reduction of their total copper content. Interestingly, mutations in SCO1 have been reported to cause fatal encephalopathy, hypertrophic cardiomyophathy, neonatal hepatopathy, and ketoacidotic comas (Stiburek et al., 2009; Valnot et al., 2000; Leary et al., 2013) , whereas mutations in SCO2 are primarily associated with neonatal hypertrophic cardiomyophathy (Jaksch et al., 2000) . Hence, SCO2 defects appear to cause a clinical phenotype resembling that seen in COA6 patients. In the case of COA6, two alleles have been identified in patients that encode COA6 with amino acid substitutions within, or in proximity to, the Cx 9 Cx n Cx 10 C motif (Baertling et al., 2015; Ghosh et al., 2014) . We therefore expressed a COA6 FLAG variant harboring the pathogenic W59C substitution and analyzed whether it affected COA6 interactions with COX2 and SCO2. After radiolabeling of mitochondrial translation products, COX2 coisolated with wildtype COA6 but not with the COA6-W59C variant ( Figure 4D ). Moreover, western blot analyses revealed that the mutant COA6 was no longer able to interact with SCO2 ( Figure 4D ). FLAG with a W59C substitution in U2OS cells and assessed mitochondrial localization by fluorescence microscopy. Both COA6 FLAG and COA6 FLAG -W59C localized to mitochondria ( Figure 4E ). To further analyze the submitochondrial localization of the W59C variant, we performed protease accessibility assays after swelling of mitochondria expressing wildtype COA6 or the mutant protein. While wild-type COA6 was sensitive to protease treatment in mitoplasts, the W59C variant was resistant, indicating protection by the inner mitochondrial membrane. These analyses point to the mislocalization of the COA6-W59C variant to the mitochondrial matrix ( Figure 4F) . Accordingly, the molecular basis for a loss of COA6-W59C function is an intramitochondrial transport defect caused by a single amino acid substitution.
Pathogenic Mutations in SCO2 Affect Its Interaction with COA6
Since expression of the pathogenic W59C allele of COA6 resulted in mislocalization of the protein, we analyzed if pathogenic mutations in SCO2 affected its ability to associate with COA6. We generated HA-tagged variants of SCO2 (SCO2 HA -R114H, SCO2 HA -R171W), mimicking mutations found in SCO2 patients.
After transfection into COA6 FLAG -expressing cells, we assessed SCO2/COA6 association. While the R171W substitution rendered SCO2 unstable, SCO2
HA -R114H remained stable in mitochondria ( Figure 5A, lanes 1-3) . The presence of the R114H substitution reduced the level of SCO2 copurifying with COA6 by 80% ( Figures 5A and 5B) . Thus, expression of a pathogenic allele of SCO2 significantly affected its interaction with COA6. Newly synthesized COX2 can be specifically coisolated together with SCO2 ( Figure 5C ). To address if a loss of COA6 affected this association, we carried out SCO2 FLAG immunoisolations after COA6 knock-down or treatment of cells with a nontargeting control. Upon reduction of COA6, the amount of newly synthesized COX2, which coisolated together with SCO2 FLAG , was significantly decreased (Figure 5D ), indicating that COA6 is required for SCO2 to bind to COX2 or to stabilize this association.
We conclude that COA6 and SCO2 interact with each other under physiological conditions to cooperate in COX2 maturation. A loss of COA6 interaction with SCO2 and/or COX2 causes cytochrome c oxidase deficiency (Figure 6 ). Moreover, the SCO2/ COX2 interaction depends on COA6. Since defects in COA6 and SCO2 function cause cardiomyopathy in humans, we suggest that the pathology of the patients is linked to tissue-specific requirements during copper incorporation into COX2.
DISCUSSION
Cytochrome c oxidase deficiency leads to a variety of severe human disorders (Ghezzi and Zeviani, 2012; Shoubridge, 2001 ). Here we find that cells lacking COA6 display a significant reduction in cytochrome c oxidase activity and total content. Moreover, SCO2 and COA6, which have been causally linked to severe cardiac disorders, physically interact. Our analyses indicate that a loss of complex formation contributes to the molecular pathology of the disorders, since pathogenic variants of SCO2 and COA6 lose their ability to interact with one another. In the case of the W59C variant of COA6, we find that the mutant protein is misrouted into the mitochondrial matrix, instead of being physiologically directed into the intermembrane space by the MIA pathway. Hence, in patient mitochondria, mutant COA6 is no longer available to its interaction partners. It is tempting to speculate that the introduction of an additional cysteine residue affects recognition of COA6 by the MIA transport machinery. However, the mechanism by which the pathogenic W59C variant is directed into the matrix will require detailed analyses on cryptic targeting signals within the COA6 protein.
SCO2 is a core constituent of the mitochondrial copper relay system that is required for metallation of COX2. Similar to SCO2 (Horng et al., 2005) , heterologously expressed COA6 purified from E. coli is copper loaded. While it is tempting to interpret this as evidence that COA6 is an active constituent of the copper relay system, direct proof that COA6 binds copper within the mitochondrial intermembrane space is still lacking. It is interesting to note, however, that the interaction between SCO2 and its substrate COX2 is affected in cells with reduced COA6 levels. Moreover, we find that the interaction between SCO2 and COA6 is lost in human cells upon treatment with thiamphenicol to block mitochondrial translation. These observations suggest that newly synthesized COX2 is required for complex formation between SCO2 and COA6. In agreement with this, BN-PAGE analyses indicate that SCO2, COX2, and COA6 form a ternary complex in human mitochondria. However, the order of events that lead to the formation of this complex remains unclear. While the interaction between COA6 and SCO proteins and the interaction of COA6 and COX2 are conserved between yeast and humans, there are a number of notable differences. Unlike the human situation, binding of Coa6 to Sco1/2 is enhanced in the absence of Cox2 in yeast, while a lack of Sco1 promotes the association between Cox2 and Coa6. Hence, the interactions between Coa6 and Sco1/2 or Cox2 appear to be mutually exclusive. Since yeast Sco1, the homolog of human SCO1 and SCO2, is dispensable for Coa6 binding to Cox2, it is conceivable that human COA6 associates with COX2 prior to SCO2 recruitment into the ternary COX2/COA6/SCO2 complex. In summary, our observations in the yeast model are in agreement with a scenario in which Coa6 acts in two distinct reaction steps, on the one hand interacting with Sco1/2 and on the other forming a complex with newly synthesized Cox2. In humans, these mutually exclusive interactions have evolved into a ternary complex formation indicative of a coupled activity that links SCO2 directly to the COX2 substrate.
We suggest a model in which in human mitochondria COA6 promotes copper transfer to COX2. This process appears to occur directly on newly synthesized COX2. In yeast, the process seems to be constituted of independent binding reactions and to occur in a sequential manner. Our data suggest that one possibility is that COA6 could transfer copper directly to COX2 after being loaded with copper by SCO proteins. Alternatively, COA6 may need to be copper-loaded to act as a chaperone to maintain the COX2 tail in a competent state for receiving copper ions from SCO proteins. Reconstitution of this process in vitro will be required to discriminate between these two mechanistic possibilities.
EXPERIMENTAL PROCEDURES
Yeast Strains, Handling, and Mitochondrial Preparation All S. cerevisiae strains used in this study are listed in Table S1 . Chromosomal deletion of COA6 was generated by introduction of the HIS3MX6 cassette (Knop et al., 1999) . Yeast strains were transformed with PCR-amplified integration-cassettes by the lithium acetate method (Ito et al., 1983) and confirmed by PCR and western blot analysis. In general, yeast cells were grown in liquid media containing 1% yeast extract, 2% peptone, and 2% galactose at 30 C with shaking (150-220 rpm). Mitochondria were isolated essentially as previously described (Meisinger et al., 2006) . For steady-state analysis of mitochondrial proteins, different amounts were subjected to SDS-PAGE, followed by western blot analysis.
Cell Culturing, siRNA Constructs, Mutagenesis, and Transfection Human embryonic kidney cell lines (HEK293T and Flp-In TM T-REx TM 293)
were cultured using DMEM supplemented with 10% (v/v) fetal bovine serum (GIBCO, Invitrogen), 2 mM L-glutamine, and 50 mg/ml uridine at 37 C under a 5% CO 2 -humidified atmosphere. For inhibition of cytosolic or mitochondrial translation, DMEM medium was supplemented with 20 mg/ml emetine (Sigma-Aldrich) for 6 hr or with 50 mg/ml thiamphenicol (Sigma-Aldrich) for 3 days, respectively. Constructs for the inducible expression of C-terminally FLAG-tagged COA6 and SCO2 were amplified by PCR using cDNA templates obtained from HEK293 cells. Primers were designed based on the sequences, Genbank: NM_001012985.2, NM_005138.2 (COA6 and SCO2, respectively). FLAG peptide sequence was introduced 5 0 of the stop codon in the reverse primer. Amplicons and pcDNA5/FRT/TO (Invitrogen) were digested with appropriate enzymes, ligated and confirmed by sequencing. Cell lines expressing the transcript of interest were generated as previously described (Dennerlein et al., 2010) . For COA6 knock-down, siRNA (5 0 -GCUUCAUCGCAGUAGGAAU-3 0 ) was used at 33 nM. Reverse transfections were performed as previously described (Mick et al., 2012) using approximately 250,000 cells/25 cm 2 , lipofectamine RNAiMAX (Invitrogen) and OPTIMEM-I medium. Cells were harvested and analyzed after 3, 4 and 6 days for growth kinetic experiments and after 4 days for biochemical experiments. Site-directed mutagenesis was carried out using the Quickchange Lightning Site-Directed transfected using 4 mg of transfection reagent and 1 mg of DNA. Cells were collected 48 hr after transfection.
RT-PCR Analysis RNA was extracted from various organs of FVB mice. Reverse transcription was performed with 2 mg of RNA and a first strand cDNA synthesis kit (Fermentas). Quantification of mRNA levels was performed using 1 ml of cDNA reaction and SYBR Green qPCR reaction kit (Clontech) and a MX3000P light cycler (Stratagene). Primers used for quantification: mS12 forward 5 0 -GAAGCTGC CAAGGCCTTAGA-3 0 , mS12-rev 5 0 -AACTGCAACCAACCACCTTC-3, COA6-forward 5 0 -CCTTCCATGAAGGAAAGGCA-3 0 , and COA6-rev 5 0 -ACTGGAA TCCTCCTGCTTCAA-3 0 .
Mitochondrial Isolation from Mammalian Cells and Localization Analysis
Mitochondria were isolated by differential centrifugation as previously described (Lazarou et al., 2009) . Protein concentration was measured by Bradford analysis using BSA as a standard. Membrane integration of proteins was determined by incubation of mitochondria with 100 mM Na 2 CO 3 (pH 10.8 or 11.5) followed by centrifugation for 30 min at 100,000 3 g at 4 C. Submitochondrial localization was analyzed by protease protection assay (Mick et al., 2012) : mitochondrial membranes were osmotically stabilized in SEM buffer (250 mM sucrose, 1 mM EDTA, and 10 mM MOPS [pH 7.2]), outer mitochondrial membrane ruptured by EM buffer (1 mM EDTA and 10 mM MOPS [pH 7.2]), or mitochondrial membranes disrupted by sonication in the presence of proteinase K. After incubation for 10 min on ice, reactions were stopped by addition of 1 mM PMSF.
Labeling of Mitochondrial Translation Products
In vivo labeling in human cells was performed as described previously (Chomyn, 1996) . Cytosolic translation was inhibited with 100 mg/ml emetine (Invitrogen) and mitochondrial translation pulsed with 0.2 mCi/ml [ 35 S]methionine for 1 hr. In vivo labeling in whole yeast cells was performed essentially as described (Mick et al., 2010) . In brief, yeast cells were resuspended in labeling buffer (40 mM potassium phosphate [pH 6.0], 2% galactose). Cycloheximide (150 mg/ml) was used to stop cytoplasmic translation. Samples were pulse-labeled with 40 mCi [ 35 S]methionine for 10 min at 30 C. To analyze the stability of mitochondrial translation products, mitochondrial translation was stopped by the addition of chloramphenicol (CAP) and excess methionine. Chase samples were taken after different time points during incubation at 30 C. To visualize radiolabeled proteins, whole-cell extracts were prepared as described above and analyzed by SDS-PAGE and digital autoradiography. For coimmunoprecipitations, translation products were labeled in isolated yeast mitochondria for 20 min with [ 35 S]methionine at 30 C, essentially as described previously (Westermann et al., 2001) . After labeling was stopped by addition of excess methionine, mitochondria were reisolated and washed with SEM buffer (250 mM saccharose, 1 mM EDTA, and 10 mM MOPS) prior to co-immunoprecipitation.
Miscellaneous
Structure of subunit II of the cytochrome c oxidase (COX2) (PDB: 3ASN) was modeled using Swiss-PDB viewer and PyMOL Molecular Graphics System, Version 1.5.0.4 Schrö dinger, LLC. Standard methods were used for SDS-PAGE and western blotting of proteins adsorbed to polyvinylidene fluoride membranes (Millipore). Primary antibodies were raised in rabbit or purchased (anti-SCO1, Abcam; anti-SCO2 and anti-COX2, Proteintech). Antigen-antibody complexes were detected by HRP-coupled secondary antibodies and enhanced chemiluminescence detection on X-ray films. Figure S1 , related to figure 1. COA6 is conserved among eukaryotes. (A) Anti-FLAG immunoprecipitation from control, MITRAC12 FLAG or COA6 FLAG -containing mitochondria. Total, 5%; eluate, 100% (WT and COA6 FLAG ) or 50% ( MITRAC12 FLAG ).
SUPPLEMENTAL INFORMATION
Samples were subjected to SDS-PAGE and Western-blotting. (B) Immunoprecipitation from digitonin-solubilized mitochondria after in organello radiolabeling of mitochondrial translation products using anti-Coa6 or control antibodies. Total, 4%; eluate, 100%.
Samples were analyzed by SDS-PAGE and digital autoradiography or Western-blotting. from digitonin-solubilized wild-type and mutant mitochondria after in organello radiolabeling of mitochondrial translation products. Total, 4%; eluate, 100%. Samples were subjected to SDS-PAGE followed by digital autoradiography and Western-blotting.
Supplemental Table T1 , related to experimental procedure. 
Enzymatic activity assays and oxygen consumption
Complex IV enzymatic activity in yeast was determined by measuring the decrease in absorbance at 550 nm in a 96-well plate reader, using reduced cytochrome c (1.5 mg/ml), 10 mM Kpi buffer pH 7.0 and yeast mitochondria. Complex III enzymatic activity was determined by measuring the increase in absorbance at 550 nm, using oxidized cytochrome c (1.5 mg/ml), 10 mM Kpi buffer pH 7.0, 12.5 mM KCN, 5 mM NADH and 
Co-Immunoprecipitation and affinity purification
COA6 or MITRAC12-specific antisera were bound to Protein A-sepharose (GE Healthcare) in 0.1 M potassium phosphate buffer (pH 7.4) and subsequently cross-linked with 5 mg/ml dimethyl pimelimidate solution in 0.1 M sodium borate (pH 9.0) for 30 min.
Mitochondria were solubilized on ice in 20 mM Tris/HCl (pH 7.4), 0.1 M NaCl, 10%
glycerol, 5 mM EDTA, 2 mM phenylmethylsulfonyl fluoride (PMSF) and 1% digitonin for 30 min. After removal of unsolubilized material by centrifugation, a sample was taken and the mitochondrial lysate incubated with anti COA6 or anti MITRAC12 coupled sepharose
